CORDIS Project
Funding breakdown and partner intelligence are Premium
Sign in and upgrade to Premium for EU contribution totals, consortium analytics, OpenAlex research context, and AI summaries. · 0 consortium intelligence fields visible of 1
Start free • Cancel anytime • 14-day refund guarantee
PROCROP aims to develop a personalized cancer vaccine targeting castration-resistant prostate cancer and ovarian cancer. The project focuses on utilizing specialized immune cells to enhance the body's ability to attack tumor cells, aiming to improve treatment outcomes.
Immune responses are initiated by antigen presentation mediated by dendritic cells (DC).
There is a minority subset of DC highly specialised in starting up cytotoxic T lymphocytes able to kill tumor cells. PROCROP aims to develop in three pilot clinical trials a suitable individualized cancer vaccine technology for castration resistant prostate cancer and metastatic cancer of the ovary that would complement currently available therapies to increase efficacy.
The project applies recent compelling…
FUNDACION PARA LA INVESTIGACION MEDICA APLICADA FIMA
Partner organizations (coordinator is shown above), with normalized type and CORDIS activity type. Guests see up to 4 partners.
STICHTING RADBOUD UNIVERSITEIT
Netherlands, Nijmegen
Type: University / higher education
Activity type: Higher or Secondary Education Establishments
SME: No
Germany, Bergish Gladbach
Type: Company (for-profit)
Activity type: Private for-profit entities (excluding Higher or Secondary Education Establishments)
SME: No
Spain, Pamplona
Type: University / higher education
Activity type: Higher or Secondary Education Establishments
SME: No
Similar projects, consortium collaboration history, frequent partners, and OpenAlex research context.
Guests see up to 5 EuroSciVoc fields.
Guests see up to 5 topics.
